Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
31 shown of 8,624 total abstracts
  1. Abstract 92962026-04-04 · 19:15 CT · E450
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-715
    M. Reck, F. Andre, C. Saura, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 99042026-04-04 · 18:15 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-874
    M. Krop, F. Andre, C. Saura, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Small Cell📄🖼️
  3. Abstract 91212026-04-03 · 21:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-460 study)
    M.C. Garassino, J. Brahmer · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 91242026-04-02 · 13:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-721
    L. Paz-Ares, C. Robert · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 90462026-04-05 · 19:15 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    M. Krop, C. Saura, L. Paz-Ares · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 98832026-04-03 · 16:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-429 study)
    C. Saura, G. Curigliano, M.C. Garassino · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 90702026-04-01 · 21:00 CT · S406
    KEYNOTE-797: Keytruda (pembrolizumab) 1L in SCLC
    M. Reck, L. Paz-Ares, T. Mok, et al. · Institut Gustave Roussy
    Education SessionLung Cancer—Small Cell📄🖼️
  8. Abstract 95742026-04-03 · 18:15 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    J. Brahmer, P. Schmid, S. Peters, et al. · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 92002026-04-04 · 21:45 CT · E450
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Modi, T. Mok · MD Anderson Cancer Center
    Education SessionLung Cancer—Small Cell📄🖼️
  10. Abstract 97312026-04-01 · 14:00 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    S. Tolaney, J. Cortes, A. Spira · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 97642026-04-02 · 19:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-103
    E. Winer, C. Saura, P. Schmid, et al. · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 90942026-04-05 · 13:15 CT · Arie Crown Theater
    Quality of life outcomes with Tagrisso in patients with NSCLC
    H. Rugo, R. Herbst, T. Mok, et al. · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 90402026-04-05 · 19:30 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-478
    S. Antonia, C. Saura, A. Spira · Mayo Clinic
    Education SessionLung Cancer—Small Cell📄🖼️
  14. Abstract 95492026-04-04 · 19:30 CT · Hall B1
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-213
    H. Borghaei, J. Brahmer, E. Winer, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 95662026-04-05 · 14:15 CT · E450
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-282 study)
    J. Cortes, C. Robert, M. Krop · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 94082026-04-05 · 13:15 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    H. Rugo, S. Modi, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 98582026-04-04 · 15:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-955
    M.C. Garassino, S. Modi, S. Peters, et al. · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 94832026-04-04 · 13:45 CT · S406
    FLAURA-324: Tagrisso (osimertinib) 2L in NSCLC
    L. Paz-Ares, M.C. Garassino, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 91272026-04-01 · 18:30 CT · E450
    DESTINY-Breast-757: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    J. Cortes, M.C. Garassino · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 91052026-04-02 · 20:45 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-314
    C. Saura, M. Krop, P. Schmid · Massachusetts General Hospital
    Education SessionLung Cancer—Small Cell📄🖼️
  21. Abstract 93282026-04-01 · 18:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-512
    E. Winer, R. Herbst, A. Spira · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 98932026-04-04 · 15:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-951
    M. Krop, F. Andre, S. Antonia · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 97392026-04-03 · 19:15 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    N. Rizvi, L. Paz-Ares, C. Saura · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 92162026-04-04 · 19:30 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    S. Peters, S. Tolaney · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 96042026-04-02 · 19:15 CT · S100A
    FLAURA-668: Tagrisso (osimertinib) neoadjuvant in NSCLC
    P. Schmid, M. Krop, F. Andre · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 99762026-04-04 · 14:45 CT · E450
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-288 study)
    G. Curigliano, F. Andre, T. Mok, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 92802026-04-04 · 20:45 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with NSCLC
    E. Winer, J. Brahmer, H. Borghaei, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract 96852026-04-01 · 16:00 CT · Hall B1
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-744
    L. Paz-Ares, H. Borghaei, C. Robert · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 91572026-04-05 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-205 study)
    M. Krop, M.C. Garassino, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 97012026-04-05 · 21:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-439
    L. Paz-Ares, M.C. Garassino, A. Spira · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 92832026-04-01 · 21:15 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-404
    S. Peters, E. Winer · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.